CCL2 and Stroke: Yan et al. (2018) also noted decreases in inflammatory factors, including plasminogen activator inhibitor type 1 (PAI‐1), monocyte chemotactic protein‐1 (MCP‐1), and matrix metalloproteinase 9 (MMP9), after stroke in rats treated with APX3330 (Yan et al., 2018).